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Nipah virus (NiV), a member of the Paramyxoviridae family, causes deadly encephalitis in humans and
huge economic losses to the pig industry. Here, we generated recombinant avirulent Newcastle disease
virus (NDV) LaSota strains expressing the NiV G and F proteins respectively (designated as rLa-NiVG
and rLa-NiVF), and evaluated their immunogenicity in mice and pigs. Both rLa-NiVG and rLa-NiVF
displayed growth properties similar to those of LaSota virus in chicken eggs. Co-infection of rLa-NiVG
and rLa-NiVF caused marked syncytia formation, while intracerebral co-inoculation of these viruses in
mice showed they were safe in at least one mammalian species. Animal immunization studies showed
rLa-NiVG and rLa-NiVF induced NiV neutralizing antibody responses in mice and pigs, and F protein-
speciﬁc CD8þ T cell responses in mice. Most importantly, rLa-NiVG and rLa-NiVF administered alone or
together, induced a long-lasting neutralizing antibody response in pigs. Recombinant rLa-NiVG/F thus
appear to be promising NiV vaccine candidates for pigs and potentially humans.
& 2012 Elsevier Inc. All rights reserved.Introduction
NiV, a member of the genus Henipavirus genus in the family
Paramyxoviridae, causes Nipah encephalitis, a deadly disease in
humans. The ﬁrst outbreak of NiV was reported in Malaysia and
Singapore in 1998. NiV then emerged in Bangladesh and India
between 2001 and 2012 (Anonymous, 2010, 2011, 2012; Hsu
et al., 2004; Luby et al., 2006). The clinical case mortality rate
ranges from 9% to 100% (Anonymous, 2012; Lo and Rota, 2008;
Wacharapluesadee et al., 2010).
NiV has the potential to be used as a bio-terrorism agent and is
listed as a BSL-4 pathogen due to its virulence in humans. Its wide
host spectrum includes pigs, dogs, cats, ferrets, African green
monkeys and horses; the fruit bat (ﬂying fox) is its natural
reservoir (Halpin et al., 2011). During the initial NiV outbreaks
in Malaysia and Singapore, most human NiV cases were caused by
close contact with pigs. In subsequent outbreaks during 2001 to
2012 in Bangladesh and India, drinking fresh date palm sap which
is contaminated by fruit bat’s droppings, urine and saliva and
close contact with infected humans were found to be the majorll rights reserved.
gb@hvri.ac.cn (Z. Bu).source of NiV infection. However, pigs are highly susceptible to
NiV and may serve as an amplifying host of the virus. Further, the
ﬁndings that most infected pigs do not show serious clinical signs
but nonetheless could shed large amount of virus make them a
dangerous infection source for humans. Of note, about 90% of
total human infections to date could be attributed to close contact
with infected pigs in the 1998 outbreak, suggesting that pig-to-
human transmission may be more efﬁcient for NiV infection.
Several Nipah vaccine candidates have been reported to induce
immune responses in immunized animals or to provide protec-
tion against NiV infection, such as recombinant canarypox-vec-
tored vaccines (Weingartl et al., 2006), recombinant vaccinia-
vectored vaccines (Guillaume et al., 2004), and soluble G protein
as a subunit vaccine (McEachern et al., 2008; Mungall et al., 2006;
Pallister et al., 2011).
Newcastle disease virus (NDV) is a member of the genus
Avulavirus in the family Paramyxoviridae. NDV strains are classi-
ﬁed as nonvirulent (lentogenic), moderately virulent (mesogenic)
or highly virulent (velogenic) for poultry (Alexander, 1989). This
virulence is determined mainly by the amino acid sequence of the
protease cleavage site of the fusion (F) protein precursor (Peeters
et al., 1999). Lentogenic strains contain fewer basic amino acids at
this site and can only be cleaved by trypsin-like extracellular
proteases that are largely conﬁned to the respiratory tract,
whereas highly virulent strains are cleaved by ubiquitous
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(Panda et al., 2004). Currently, lentogenic strains, such as the
LaSota strain, are used as live vaccines against NDV in poultry
(Alexander, 1997).
NDV has been actively developed and evaluated as a vaccine
vector for the control of human and animal diseases (Bukreyev
and Collins, 2008; Bukreyev et al., 2006; DiNapoli et al., 2010a,
2010b; Ge et al., 2007; Ge et al., 2010; Khattar et al., 2010;
Kortekaas et al., 2010). It has potential as a vaccine vector for
many reasons, including that it does not usually result in a
productive infection in mammals and the pre-existing immunity
and maternal antibody to mammalian paramyxoviruses does not
interfere with the replication of NDV as NDV is antigenically
distinct from the mammalian paramyxoviruses. Its safety in many
animal models, including African green and rhesus monkeys, as
well as humans, has been demonstrated (Bukreyev and Collins,
2008; Bukreyev et al., 2006; DiNapoli et al., 2010a, 2010b; Ge
et al., 2007; Ge et al., 2010; Khattar et al., 2010; Kortekaas et al.,
2010).
The glycoprotein (G) and fusion protein (F) are two major NiV
surface glycoproteins that stimulate protective immune res-
ponses (Guillaume et al., 2004; Weingartl et al., 2006). Here, we
have used an established reverse genetics system to generate two
recombinant NDV LaSota viruses that express either NiV G or F
protein and we have evaluated the immunogenicity of these two
recombinant viruses in mice and pigs.Materials and methods
Viruses, cells and puriﬁed G and F proteins
BHK-21 and 293 T cells used for virus rescue and titration
were maintained in complete Dulbecco’s modiﬁed eagle medium
(DMEM) containing 10% fetal bovine serum (FBS). Recombinant
NDV strains were grown and titrated in 9-day-old speciﬁc-
pathogen-free (SPF) embryonated chicken eggs by inoculation of
the allantoic cavity. The Vesicular Stomatitis Virus (VSV) pseudo-
typed assay system (Takada et al., 1997) was kindly provided by
Dr. Michael Whitt (University of Tennessee Health Science Cen-
ter). The pseudotyped VSVDGnGFP virus particle, which packaged
the Nipah virus G and F proteins on the viral envelope (designated
as VSVDGnGFP-NiVG/F), were prepared and used as a substitute
for live NiV in the serum neutralization test. The titer of
VSVDGnGFP-NiVG/F pseudotyped virus was determined by infec-
tion of BHK21 cells and counting the number of GFP expressing
cells under a ﬂuorescence microscope as previously described
(Wang et al., 2006a), and calculated by using the method of Reed
and Muench (Reed and Muench, 1938). Stocks of prepared
pseudotyped virus were stored at 70 1C. Recombinant baculo-
virus expressing G-his or F-his fusion protein (G or F was fused
with a histag segment HHHHHH at its C-terminus) was generated
and used to infect Sf9 insect cells. At 96 h post-infection, cells
were harvested and lysed, and the G-his or F-his protein released
into the lysing buffer was puriﬁed using Ni-NTA agarose beads
(QIAGEN, Valencia, CA). Puriﬁed proteins were characterized by
Coomassie blue staining and Western blot.
Plasmid construction and virus rescue
To construct the full-length recombinant genomic cDNA, the
cDNA of the NiV G and F genes were ampliﬁed from synthesized G
and F cDNA (Invitrogen, Shanghai, China) by using the following
primers: to amplify the G gene, 5’-GACTGTTTAAACttagaaaaaa-
TacgggtagaaCgccaccATGCCGGCAGAAAACAAGAAAGTTAG-3’ and
5’–CTGAGTTTAAACGTTATGTACATTGCTCTGGTATC-3’; and toamplify the F gene, 5’-GACTGTTTAAACttagaaaaaaTacgggtagaaCgc-
caccATGGTAGTTATACTTGACAAGAGATG-3’ and 5’- CTGAGTT-
TAAACGCTATGTCCCAATGTAGTAGAG-3’. Both the G and F genes
were ﬂanked by the restriction endonuclease Pme I (boldface
letters); In order to form a NDV L protein recognizable transcrip-
tion unit, the NDV gene start sequence (GS, 5’-acgggtagaa-3’) and
gene end sequence (GE, 5’-ttagaaaaaa-3’) were presented before
the optimal Kozak sequence (italic lowercase letters) and the NiV
G or F gene sequences (underlined uppercase letters). The
ampliﬁed G and F genes were digested by Pme I and then inserted
into the P-M intergenic region at nucleotide position 3165 of the
NDV genome, as described previously (Ge et al., 2007). The
resultant plasmids were designated as prLa-NiVG and prLa-NiVF
and were used for virus rescue by means of reverse genetics as
described previously (Ge et al., 2007). The presence of recombi-
nant NDV expressing NiV G and NiV F was conﬁrmed using IFA
and RT-PCR. The resultant recombinant viruses were designated
as rLa-NiVG and rLa-NiVF.
Immunoﬂuorescence
NDV infection of cultured cells was detected by means of an
IFA with chicken serum against NDV as previously described (Ge
et al., 2007). For confocal assays, BHK-21 cells were grown in 24-
well plates or plated on cover slips in 35-mm diameter dishes and
infected with NDV rLa, rLa-NiVG, or rLa-NiVF. At 24 h post-
infection, cells were ﬁxed in pre-chilled 3% paraformaldehyde in
phosphate-buffered saline (PBS) for 15 min at room temperature,
washed with PBS three times then blocked with PBS containing
1% (wt/vol) bovine serum albumin (BSA) at room temperature for
1 h. Cells were then incubated with mouse monoclonal antibodies
(G3E9 for G protein, F2G1 for F protein, prepared in our lab) or
chicken serum against NDV for 1 h at room temperature. Cells
were then washed three times with PBS containing 0.05% Tween
20 and stained with an FITC-conjugated goat anti-mouse antibody
(Sigma) or a TRITC-conjugated rabbit anti-chicken antibody
(Sigma) for 30 min. Cells were washed three times with PBS then
their nuclei were stained with DAPI. Cells were analyzed with a
ﬂuorescence microscope or confocal laser microscope. Images
were acquired with a Zeiss (Thornwood, N.Y.) Axioscop micro-
scope equipped for epiﬂuorescence with a Sensys charge-coupled
device camera (Photometrics, Tucson, Ariz.) by using IPLab soft-
ware (Scanalytics, Vienna, Va.).
Assessment of virus pathogenicity
To determine the pathogenicity of rLa-NiVG and rLa-NiVF in
poultry, the mean death time (MDT), intracerebral pathogenicity
index (ICPI), and intravenous pathogenicity index (IVPI) were
determined in embryonated SPF chicken eggs or in SPF chickens
according to the OIE Manual(OIE, 2011). To assess the pathogeni-
city of the recombinant viruses in mice, two groups of 10 six-
week-old female Balb/c mice (Vital River, Beijing, China) were
intramuscularly (i.m.) injected with 0.1 ml of diluted allantoic
ﬂuid containing 108 EID50 (50 percent Embryo Infectious Dose)
rLa-NiVG/F (a mix of rLa-NiVG and rLa-NiVF) or rLa and intrana-
sally (i.n.) inoculated with 0.03 ml of diluted allantoic ﬂuid
containing 3107 EID50 rLa-NiVG/F or rLa. The third group of
10 mice were i.m. injected with 0.1 ml and i.n. inoculated with
0.03 ml PBS as mock infection control. Mice were monitored
daily for weight changes. To test whether co-infection of rLa-
NiVG and rLa-NiVF was safe, 4 groups of 10 three-week-old
female Balb/c mice were intracerebrally (i.c.) inoculated with
0.03 ml of diluted allantoic ﬂuid containing 3107 EID50 rLa,
rLa-NiVG, rLa-NiVF or rLa-NiVG/F. Another group of 10 mice were
i.c. inoculated with 0.03 ml of PBS as mock infection control. Mice
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Fig. 1. Generation of recombinant NDV expressing the NiV G and F genes.
(A) Schematic representation showing the rLa genome with the restriction
endonuclease Pme I site introduced between the P and M genes and the NiV G
and F genes inserted into the Pme I site. (B) Indirect immunoﬂuorescence staining
of rLa-NiVG- and rLa-NiVF-infected BHK-21 cells with chicken anti-NDV serum
and mouse monoclonal antibodies to the NiV G (G3E9) or NiV F (F2G1) protein and
observed with a confocal laser microscope.
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loss, or death.
Immunization of mice and pigs
For mouse immunization, 6-week-old female Balb/c mice (Vital
River, Beijing, China) were i.m. vaccinated with each recombinant
virus at a dose of 108 EID50 in 100 ml of diluted allantoic ﬂuid. Four
weeks after the ﬁrst dose, the mice were boosted with the same
vaccine at the same dose and via the same route. To assess F
protein-speciﬁc CD8þ T cell responses, we prepared splenocytes
from rLa-NiVF-immunized mice 10 day after the ﬁrst or second
vaccine dose. For the serological assay, two weeks after each dose,
mouse blood samples were collected from the retro-orbital sinuses
under isoﬂurane inhalation anesthesia.
For pig immunization, ﬁve groups (ﬁve each) of four-week-old
crossbred Landrace pigs were obtained and housed at the Experi-
mental Animal Center of Harbin Veterinary Research Institute. Three
groups were i.m. inoculated with rLa-NiVG, rLa-NiVF, or a mix of rLa-
NiVG and rLa-NiVF (rLa-NiVG/F) at a dose of 2109 EID50 in 2 ml of
diluted allantoic ﬂuid. The fourth group was inoculated i.m. with rLa
at a dose of 2109 EID50 in 2 ml of diluted allantoic ﬂuid, and the
ﬁfth group was i.m. immunized with 2 ml of PBS. Four weeks after
the ﬁrst dose, the pigs were boosted with the same vaccine at the
same dose and via the same route. Serum was collected before
vaccination and at week 2, 3, 4, 5, 7, 9, 13, 21, and 29 after prime.
ELISA
NiV G and F protein-speciﬁc antibodies were measured in
individual mouse or pig sera by means of an enzyme-linked
immunoabsorbent assay (ELISA). For mouse serum, 96-well ELISA
plates were coated overnight at 4 1C with puriﬁed His-tagged G or
F protein at a concentration of 4 mg/ml. The plates were then
washed and blocked with 2% BSA-PBST (PBS containing 0.05%
Tween-20 (v/v) and 2% bovine serum albumin (BSA, wt/v) ) at
room temperature for 1 h. Serially diluted serumwas added to the
ELISA plate, and incubated at room temperature for 1 h. Plates
were washed three times with PBST, then a 1:4000 dilution of
HRP-labeled goat anti mouse IgG (Southern Biotech, Birmingham,
AL) was added and incubated for another 1 h at room tempera-
ture. The plates were washed thoroughly ﬁve times with PBST,
and any remaining ﬂuid was decanted completely from each
plate. For visualization, 50 ml of 3,3’,5,5’-Tetramethylbenzidine
(TMB) liquid substrate (Sigma) was added to each well for 5 min
at room temperature; 50 ml of 0.2M hydrochloric acid was added
to stop the reaction. O.D values were determined with a Model
680 microplate reader (Biorad) at 450 nm. A standard curve was
generated by coating each ELISA plate with serial 2-fold dilutions
of mouse IgG (Southern Biotech, Birmingham, AL) at known
concentrations. A linear equation was obtained based on the
2-fold decreased standard IgG concentration and their O.D values,
thus the concentration of NiV G and F protein-speciﬁc antibodies
in each sample could be calculated according to the linear
equation by their O.D values and expressed as the amount of
antigen-speciﬁc IgG per ml of serum (ng/ml). The protocol of
ELISA for pig serum is basically the same as the ELISA for mouse
serum. The differences were all pig sera were used at 1:1000 ﬁxed
dilution, and due to the lack of puriﬁed pig IgG to build standard
curves, the pig sera ELISA results were expressed as the relative
O.D values to the negative controls.
Neutralization assay
NiV speciﬁc neutralizing antibody levels were determined
using pseudotyped VSV in place of live NiV as described by Wanget al. (Wang et al., 2006a). Pseudotyped VSV (VSVDGnGFP) has the
VSV envelope protein G gene replaced by the green ﬂuorescent
protein (GFP) gene and complemented with the VSV G protein
expressed in trans. VSVDGnGFP-NiVG/F pseudotyped virus was
prepared by co-transfecting 293T cells with pCAGG-G and
pCAGG-F and then infecting those cells with VSVDGnGFP. The
recombinant pseudotyped virus VSVDGnGFP-NiVG/F has GFP and
either the NiV G or F protein incorporated into its VSV envelope.
VSVDGnGFP-NiVG/F can mimic the infection of real NiV, entering
NiV permissive cells by F- and G-mediated fusion. The titer of
VSVDGnGFP-NiVG/F was determined in BHK-21 cells by counting
the ﬂuorescent cells in an infectivity assay, and calculated by
using the method of Reed and Muench. The titer is typically
around 3106 TCID50/ml. VSVDGnGFP-NiVG/F was aliquoted and
stored at 80 1C. To perform the neutralization assay, 25 ml of
2-fold serially diluted serum (heat inactivated at 56 1C for 30 min
before use, initial dilution was 1:4) was mixed with 25 ml of
DMEM containing 5102 TCID50 VSVDGnGFP-NiVG/F and incu-
bated at 37 1C for 1 h. After the incubation, 50 ml of the mixture
was added to the BHK-21 cells in triplicate wells of a 96-well
plate. The GFP-expressing cells were counted at 16 h post-infec-
tion under a ﬂuorescence microscope. Neutralization titers were
expressed as the reciprocal of the highest dilution of serum that
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as compared with the negative control.
To assess the level of the neutralizing antibodies against the
NDV vector virus, a recombinant NDV LaSota virus expressing the
enhanced green ﬂuorescent protein (designated as rLa-EGFP) was
constructed and titrated before use. Brieﬂy, 25 ml of 2-fold serially
diluted serum (initial dilution¼1:50) was mixed with 25 ml of
medium containing 2103 EID50 of rLa-EGFP at 37 1C for 1 h.
After the incubation, 50 ml of the mixture was added to the BHK-
21 cell monolayer in triplicate wells of a 96-well plate. The GFP-
expressing cells were counted at 16 h post-infection under a
ﬂuorescence microscope. Neutralization titers were expressed as
the reciprocal of the highest dilution of serum that showed at
least a 50% reduction in the number of ﬂuorescent cells as
compared with the negative control.
Flow cytometric analysis of the mouse CD8þ T cell response
The NiV F protein-speciﬁc CD8þ T cell response in Balb/c mice
was determined by using ﬂow cytometry with established proto-
cols as previously described (Wen et al., 2009). rLa-NiVF-immu-
nized mice were sacriﬁced on day 10 after the ﬁrst and secondrLa
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Fig. 2. Growth properties of recombinant viruses in embryonated eggs. rLa, rLa-
NiVG, and rLa-NiVF were inoculated into the allantoic cavities of 10-day-old
embryonated eggs at a dose of 100 EID50 in 0.1 ml, and the allantoic ﬂuid of six
eggs from each group was harvested at the time points indicated and pooled for
EID50 determination in eggs. The data shown were acquired from three indepen-
dent experiments and presented as the mean 7SD of 10 eggs for each group.
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Fig. 3. Syncytia formation and inhibition assay. Conﬂuent monolayers of BHK-21 cells w
anti-NDV serum, mouse anti-NiVG or mouse anti-NiVF serum was added to the superna
and detected with chicken anti-NDV serum, then incubated with an FITC-conjugated rimmunizations. Mouse splenocytes were prepared as reported by
Ye et al. (Ye et al., 2004). Brieﬂy, spleens were removed from the
euthanized mice, cut into small pieces, and then homogenized by
gently rubbing. After low-speed centrifugation, the supernatant
was removed and the cells were gently resuspended in red blood
cell lysing buffer (Sigma) and incubated on ice for one min.
Splenocytes were stimulated with 20 mg/ml of NiV F-speciﬁc
CD8 peptide (VYFPILTEI, H2Kd, unpublished) or an unrelated
peptide (AMQMLKETI, which corresponds to a epitope in the
HIV Gag protein) for 6 h in presence of 10 ng/ml of Brefeldin A
(eBioscience, San Diego, CA) to assess the CD8þ T cell response. A
positive control was prepared by stimulating the splenocytes with
10 ng/ml of phorbol 12-myristate 13-acetate (PMA) (Sigma) and
500 ng/ml of ionomycin (Sigma). After stimulation, the cells were
washed twice with PBS containing 3% fetal calf serum and then
stained with Peridinin-Chlorophyll-Protein-Complex (PerCP)-conju-
gated rat anti-mouse CD8 and phycoerythrin (PE)-conjugated rat
anti-mouse CD3 antibodies (BD Pharmingen, San Diego, CA). Cells
were then ﬁxed and permeabilized with Fix&Perm buffers
(eBioscience, San Diego, CA) and stained for intracellular interferon-
gamma (IFN-g) with an allophycocyanin (APC)-conjugated rat anti-
mouse IFN-g antibody (BD Pharmingen, San Diego, CA). The levels of
CD8þ T cell responses were determined by using ﬂow cytometry on
a BD FACSAria Station (BD Immunocytometry Systems, San Jose, CA).
Data were analyzed with FlowJo software (Treestar Inc, Ashland, OR).
Statistical analysis
Data on virus titers, antibody titers and mouse T cell responses
were analyzed by using the Student’s t test with the Excel
program (Microsoft, Redmond WA).Results
Generation of recombinant NDV expressing the NiV G and F genes
Recombinant NDV expressing the NiV G and F genes were
generated by inserting the NiVG or NiVF gene between the P and
M genes in the genome cDNA of NDV (Fig. 1A). The presence of
the inserted gene was conﬁrmed by RT-PCR and the expression ofrLa-NiVG/F
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rLa-NiVG/F
+anti-G serum
rLa-NiVG/F
+anti-F serum
rLa-NiVG/F
+naïve mice serum
5 6 7 8
ere infected with rLa, rLa-NiVG, rLa-NiVF, or rLa-NiVG/F at a MOI of 0.05. Chicken
tant 1 h post-infection at a dilution of 1:50. Cells were ﬁxed at different time points
abbit anti-chicken antibody.
6000
IgG against G protein
a
I
D. Kong et al. / Virology 432 (2012) 327–335 331the G and F genes conﬁrmed by indirect confocal immunoﬂuor-
escence staining of rLa-NiVG- and rLa-NiVF-infected BHK-21 cells.
rLa-NiVG- and rLa-NiVF-infected BHK-21 cells stained with the
NiVG protein-speciﬁc monoclonal antibody G3E9 and the NiVF
protein-speciﬁc monoclonal antibody F2G1, respectively, whereas
rLa-infected BHK-21cells were not stained by either G3E9 or F2G1
(Fig. 1B). NDV antigens and NiV G or F protein also co-localized on
the surface of the BHK-21 cells, thus conﬁrmed the surface
expression of NiV G and F protein (Fig. 1B).
The growth properties of rLa, rLa-NiVG, and rLa-NiVF were
examined in embryonated chicken eggs. All three viruses grew to
similar levels; rLa-NiVG and rLa-NiVF reached peak titers of
9.7 logEID50/ml and 9.65 logEID50/ml respectively at 72 h post-
inoculation (Fig. 2). The genetic stability of the NiV G or F gene
within rLa-NiVG or rLa-NiVF was assessed by serially passagingrLa-NiVG/F
rLa
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Fig. 4. Pathogenicity of the recombinant viruses in chickens and mice.
(A) Pathogenicity assay in SPF eggs and chickens. The mean death time (MDT),
intracerebral pathogenicity index (ICPI), and intravenous pathogenicity index
(IVPI) were determined as described in the Materials and methods. (B) Weight
change in mice inoculated with recombinant and vector viruses. Groups of 10
mice were inoculated (I) i.m. with 108 EID50 (in 100 ml) of rLa-NiVG/F, rLa and PBS
and (II) i.c. with 3107 EID50 (in 30 ml) of rLa, rLa-NiVG, rLa-NiVF or rLa-NiVG/F.
Mice were observed and weighed daily for 14 (I) and 18 (II) days, respectively. All
mice survived the duration of the experiment. Body weight changes for each group
are shown as ratios of the body weight at day 0, which was set as 100.the virus in SPF chicken eggs 10 times. After 10 passages, both the
presence and expression of the NiV G or F gene was conﬁrmed by
RT-PCR and immunoﬂuorescence (data not shown).
As a low pathogenicity NDV strain, rLa infected individual cells
but did not spread to adjacent BHK-21 cells in the absence of
exogenous trypsin. Therefore, as shown in Fig. 3, the percentage
of infected cells at 96 h post-infection was almost identical to that
at 24 h post-infection. This property was not altered by the
insertion and expression of the NiV G or F gene. Co-infection of
rLa-NiVG and rLa-NiVF resulted in syncytia formation on BHK-21rLa-NiVG
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Fig. 5. Immunization of mice. Groups of ten mice each received two doses of 108
EID50 of rLa-NiVG, rLa-NiVF, or rLa-NiVG/F i.m. with a 4-week interval. Blood
samples were collected two weeks after the ﬁrst dose (prime) and the second dose
(boost) for antibody assays. The ELISA antibody (A) against the NiV G protein
(I) and the NiV F protein (II) and the neutralization antibody against NiV (B) for
each group were determined as described in the Materials and methods. Data are
presented as the mean 7SD of 10 mice for each group. (a), (b), and (c): Po0.05,
signiﬁcance of the difference in antibody amount after the second dose compared
with the corresponding value after the ﬁrst dose of virus.
D. Kong et al. / Virology 432 (2012) 327–335332cells that increased in size with time (Fig. 3). The addition of 1:50
diluted chicken anti-NDV serum to the cell culture supernatant
had no effect on syncytia formation or growth (Fig. 3). In contrast,
anti-NiVG or -NiVF serum (1:50 dilution) from pCAGG-NiVG- or
pCAGG-NiVF-immunized mice (Wang et al., 2006a) inhibited
syncytia formation when added to the supernatant of rLa-NiVG/
F pre-infected BHK-21 cells.
Expression of the NiV G and F proteins does not increase the virulence
of the NDV vector in chickens and mice.
To investigate whether the expression of the NiV G or F genes
alters the pathogenicity of the NDV vector, we compared the
biological character and pathogenicity of rLa-NiVG and rLa-NiVF
with their vector, rLa, in chickens and mice. The MDT, ICPI, and IVPIPrime
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Fig. 7. Neutralizing antibodies and ELISA antibodies in pigs. Pigs were immunized with two doses of 2109 EID50 of recombinant viruses with a 4-week interval. Blood
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as described in the Materials and Methods. Data for the neutralization titers to NiV were presented individually, and the data for the neutralization titers to NDV were
presented as the mean 7SD of ﬁve pigs for each group. The ELISA antibodies (B) against the NiV G protein (I) and the NiV F (II) protein for each group were determined as
described in the Materials and methods. Data are presented as the mean 7SD of ﬁve pigs for each group.
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mals, we inoculated mice i.m. with 108 EID50 of rLa or a mix of
rLa-NiVG and rLa-NiVF (rLa-NiVG/F) in 100 ml of diluted allantoic
ﬂuid, and at the same time inoculated the mice i.n. with 3107
EID50 of rLa or rLa-NiVG/F in 30 ml of diluted allantoic ﬂuid. The
mice were observed daily for two weeks for signs of weight
change or sickness. rLa- and rLa-NiVG/F-infected mice showed
similar body weight changes to those of mock-infected mice and
no signs of disease were observed (Fig. 4B I). Because NiV
infections in animals can cause severe encephalitis, largely due
to syncytia formation induced by the NiV G and F proteins, we
further tested whether i.c inoculation of rLa-NiVG/F was safe for
3-week-old mice. After i.c inoculation with 3107 EID50 of rLa,
rLa-NiVG, rLa-NiVF, or rLa-NiVG/F, mice from each group endured
a period of weight loss from day 2 to day 7, with maximumweight loss (less than 15%) observed at days 2 and 3 (Fig. 4B II).
Mice started gaining weight from day 7 and almost recovered
fully by day 8. Thereafter, all of the mice continued to gain weight
normally. The weight change patterns of the mice inoculated with
rLa-NiVG, rLa-NiVF, and rLa-NiVG/F were almost identical to
those of rLa- and PBS-inoculated mice. This result demonstrates
the safety of the recombinant viruses in at least one mammalian
species.
The recombinant viruses rLa-NiVG and rLa-NiVF induces Nipah-
speciﬁc humoral and CD8þ T cell responses in mice
To evaluate the potential of rLa-NiVG and rLa-NiVF as NiV
vaccines, four groups of mice (10 mice each) were immunized i.m.
with 108 EID50 of rLa-NiVG, rLa-NiVF, a mix of rLa-NiVG and rLa-
D. Kong et al. / Virology 432 (2012) 327–335334NiVF (rLa-NiVG/F), or with rLa in 100 ml of diluted allantoic ﬂuid.
Four weeks after the ﬁrst dose, the mice were boosted with the
same dose via the same route. Serum samples were collected
2 weeks after the ﬁrst dose and 2 weeks after the second dose for
ELISA and neutralizing assays. NiV G- (Fig. 5A I) and F- (Fig. 5A II)
speciﬁc IgG from each group was detected by ELISA. The IgG
antibody levels were signiﬁcantly boosted after the second dose
(Po0.05). The serum neutralizing antibodies were then analyzed
using a NiV G/F pseudovirus neutralization assay. As shown in
Fig. 5B, rLa-NiVG, rLa-NiVF, and rLa-NiVG/F induced similar levels
of NiV neutralizing antibodies after the ﬁrst dose, although the
levels were not high; whereas after the second dose the neutra-
lizing antibodies were boosted signiﬁcantly (Po0.05).
To investigate whether the recombinant viruses could elicit T
cell responses (especially CD8þ T cell responses), a NiV F protein
mouse CD8 epitope-F280 (VYFPILTEI, H2Kd, unpublished) was
identiﬁed by using bioinformatics prediction and ﬂow cytometry
veriﬁcation. Using the same approach, however, we were unable
to ﬁnd any CD8 epitopes in the G protein from fourteen
synthesized peptides. Therefore we could only evaluate the rLa-
NiVF-induced CD8þ T cell responses. As shown in Figs. 6A and B,
rLa-NiVF immunization induced signiﬁcant F280-speciﬁc IFN-g-
producing CD8þ T cell responses after the ﬁrst dose and these
responses were signiﬁcantly boosted after the second dose
(po0.05).
rLa-NiVG and rLa-NiVF elicit high-level, long-lasting NiV virus-
speciﬁc neutralizing antibodies in pigs
The levels and duration of the recombinant virus-induced
neutralizing antibody response are shown in Fig. 7. For rLa-NiVG-
(Fig. 7A I) and rLa-NiVG/F- (Fig. 7A III) immunized pigs, NiV-
neutralizing antibodies were detected shortly after priming and
were boosted after the second dose. The neutralizing antibodies
lasted for at least 21 weeks (Fig. 7A I and III) and had reduced to a
very low level by 29 weeks. No signiﬁcant difference in neutraliz-
ing antibody titers was found between the rLa-NiVG and rLa-
NiVG/F groups at any time point. The level of neutralizing anti-
body to NiV in the rLa-NiVF group (Fig. 7A II) was lower than that
in the rLa-NiVG and rLa-NiVG/F groups for the overall 29-week
observation period. Serum antibodies against puriﬁed His-tagged
NiV G or F proteins were measured by ELISA after the primary and
secondary immunization. Compared with the neutralizing anti-
bodies, the ELISA antibodies were also boosted, and gradually
increased after the second dose (Fig. 7B). NDV neutralizing
antibodies were detected after the primary immunization and
were boosted after the second dose (Fig. 7C) but no statistical
difference in NDV neutralization antibody titers was seen
between the rLa-NiVG, rLa-NiVF, and rLa-NiVG/F groups during
the 29-week observation period.Discussion
Nipah virus is a deadly emerging infectious pathogen that
poses a huge public health threat. Development of NiV vaccines is
important both to protect susceptible animals and to reduce
transmission from animals to humans (Guillaume et al., 2004;
McEachern et al., 2008; Mungall et al., 2006; OIE, 2011; Weingartl
et al., 2006). In this study, we used reverse genetics to construct
recombinant NDV, rLa-NiVG and rLa-NiVF, which express the NiV
glycoprotein (G) and fusion (F) proteins respectively. rLa-NiVG
and rLa-NiVF maintained high growth titers in embryonated eggs
and low pathogenicity in poultry and mice. The recombinant
viruses induced signiﬁcant NiV-speciﬁc neutralizing antibodies in
mice and long-lasting NiV-speciﬁc neutralizing antibodies in pigs.Our ﬁndings thus show that rLa-NiVG and rLa-NiVF are safe and
promising candidate vaccines against NiV infection.
Interestingly, rLa-NiVG was better able than rLa-NiVF to
induce neutralizing antibodies, which is similar to observations
from previous studies on other paramyxovirus, such as NDV, SeV,
NiV and PPRV(Chen et al., 2010; Orvell and Norrby, 1977; Seto
et al., 1974; Umino et al., 1984; Wang et al., 2006a; Weingartl
et al., 2006) Biosafety level-4 containment is required to work
with Nipah virus due to its pathogenicity. This made it impossible
for us to do challenge studies or the neutralization assay using
live NiV. The VSV pseudotyped virus system has been successfully
used in neutralization assays for enveloped viruses such as Ebola,
Nipah, and Hantavirus (Ito et al., 2001; Ogino et al., 2003; Takada
et al., 1997; Tamin et al., 2009). In this study, we used
VSVDGnGFP-NiVG/F pseudotyped virus to mimic authentic NiV
in a serum neutralization test. The pseudotyped particles are easy
to prepare and render high level biosecurity containment unne-
cessary. In addition the assays are sensitive and rapid.
The role of CD8þ CTLs in controlling viral infections has been
well documented. One advantage of using live vectored vaccines
is that they elicit good cellular responses (Mathew et al., 2005;
Song et al., 2011; Wang et al., 2006b). Splenocytes from rLa-NiVF
immunized mice elicited high level CD8þ T cell responses when
stimulated with an F protein-derived Balb/c mouse CD8þ T cell
epitope. To our knowledge, this is the ﬁrst identiﬁcation of a CD8
epitope of F protein in Balb/c mice. Unfortunately, due to the
unclear MHC background of the crossbred pigs, we were unable to
identify pig CD8þ T cell epitopes in the NiV G or F protein, and,
therefore, we could not measure epitope-speciﬁc CD8þ T cell
responses in immunized pigs.
The co-expression of the NiV G and F proteins in permissive
cells causes syncytia formation. It is essential to evaluate whether
co-infection of two viruses is safe in mammalian systems. Our
results showed that even when a high dose of rLa-NiVG/F was
injected into a 3-week-old mouse brain, the weight change
pattern and post-injection behavior were almost exactly the same
as those of groups that were injected with PBS, rLa, rLa-NiVG
alone or rLa-NiVF alone. In addition, there was no signiﬁcant
difference in serum NiV-speciﬁc IgG or neutralizing antibodies
between rLa-NiVG- and rLa-NiVG/F-vaccinated mice and pigs, and
the levels of NDV-neutralizing antibody induced by co-infection
of rLa-NiVG/F in pigs were similar to those induced by rLa-NiVG
or rLa-NiVF alone. These results indicate that the co-infection
with rLa-NiVG/F is safe and did not result in enhanced virus
replication in vaccinated animals.
Weingartl et al. showed that canarypox vectored NiV vaccines
(ALVAC-G and ALVAC-F) were effective in eliciting antibodies
against NiV and could provide complete protection for pigs
against lethal NiV challenge (Weingartl et al., 2006). The success
of canarypox-based NiV vaccines demonstrated protection
against NiV infection in pigs can be achieved by live-attenuated
vectored-NiV vaccines. Compared with canarypox virus, NDV-
vectored vaccines have several advantages: they are easy to
culture and grow to high titers in chicken eggs; they do not
require complicated cell culture equipment and are thermostable
when lyophilized. These features make NDV-based Nipah vac-
cines feasible and accessible especially to rural areas. In areas
frequented by fruit bats, rLa-NiVG and rLa-NiVF could be used to
decrease the susceptibility of pigs and other animals to NiV
infection. During outbreaks of NiV, infection of pigs or other
animals that are in close contact with humans may facilitate
human infection by NiV and lead to sustainment of the outbreak.
Therefore, application of these recombinant vaccines in these
susceptible animals will be important for protecting them from
NiV infection and thus preventing sustained NiV transmission to
humans from these animal hosts. In addition, given their safety
D. Kong et al. / Virology 432 (2012) 327–335 335and versatile applications, rLa-NiVG and rLa-NiVF maybe have the
potential to serve as human NiV vaccines, such as health care
people and researchers who face the threat of NiV infection in the
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